The Global Gaucher Disease Treatment Market is set for steady growth through 2031, driven by rising diagnosis rates, expanding access to enzyme replacement therapy, and late-stage innovations targeting neuronopathic forms, with notable momentum from pipeline assets such as venglustat, PR001, and FLT201 in key regions including the US, EU4/UK, Japan, and LATAM. Executive summary The market for...